Crinetics Pharmaceuticals (CRNX) Prices ~4.6M Shares at $16.44

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced today the pricing of an underwritten public offering of 4,562,044 shares of its common stock at a price to the public of $16.44 per share. All of the shares to be sold in the offering are being sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $75.0 million. The offering is expected to close on or about April 12, 2021, subject to the satisfaction of customary closing conditions.

Crinetics intends to use the net proceeds from the proposed offering to fund the development of paltusotine and its other research and development programs, and for working capital and general corporate purposes.

SVB Leerink is acting as sole bookrunning manager for the offering.

You May Also Be Interested In

• Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh
• Enliven Therapeutics, Inc (ELVN) Files for 6.43M Share Offering by Selling Stockholders
• General Dynamics (GD) Files for Offering of Debt Securities